(Q34470208)

2 August 2017

1 reference

title

A review of the potential role of methylnaltrexone in opioid bowel dysfunction (English)

1 reference

2 August 2017

0 references

J F Foss

1

1 reference

PubMed ID

11755893

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The American Journal of Surgery

2 August 2017

1 reference

2 August 2017

182

1 reference

2 August 2017

5A Suppl

1 reference

2 August 2017

19S-26S

1 reference

Side effects of morphine administration in cancer patients

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

A long-term survey of morphine in cancer pain patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Management of opioid-induced constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Prevention of opioid side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Incidence, prevalence, and management of opioid bowel dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Gut motility and transit changes in patients receiving long-term methadone maintenance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Morphine, constipation and performance status in advanced cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Assessment of nalmefene glucuronide as a selective gut opioid antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

The central and peripheral influences of opioids on gastrointestinal propulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Treatment of opioid-induced constipation with oral naloxone: A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Oral naloxone reverses opioid-associated constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

The use of quaternary narcotic antagonists in opiate research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

Oral methylnaltrexone for opioid-induced constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900783-8

10.1016/S0002-9610(01)00783-8

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11755893